

ANISHA GULATI, M.D., M.B.A.

www.dranishagulati.com • 772-919-1060 • anisha.gulati@holisticmh.org

EXPERIENCED BOARD-CERTIFIED PSYCHIATRIST WITH LEADERSHIP EXPERIENCE AND CLINICAL RESEARCH EXPERIENCE DEDICATED TO IMPROVING QUALITY, SAFETY AND VALUE OF BEHAVIORAL HEALTHCARE AS WELL AS IMPROVING ACCESS THROUGH INNOVATION AND EDUCATION

EXPERIENCE

JUNE 2023– PRESENT

SUB-INVESTIGATOR, CLINICAL TRIALS, HEALTH SYNERGY CLINICAL RESEARCH, NEUROBEHAVIORAL HOSPITALS • WEST PALM BEACH, FL

- Running clinical trials by Merck, Teva, performed in inpatient psychiatric setting.

AUGUST 2022– PRESENT

CONSULTATION-LIASON PSYCHIATRIST, VETERANS ADMINISTRATION • WEST PALM BEACH, FL

- Provide part time psychiatric care to Veterans on inpatient psychiatric unit as well as provide consultation services for Veterans admitted to medical units

JULY 2022– PRESENT

OUTPATIENT PSYCHIATRIST, TALKIATRY • FLORIDA and NEW YORK

- Provide outpatient psychiatric services to patients through telepsychiatry startup company

- Engage physicians around quality, patient experience and process improvement

FEBRUARY 2019 – MAY 2022

CHIEF MEDICAL OFFICER, CORAL SHORES BEHAVIORAL HEALTH/ UHS • STUART, FL

- Oversee daily clinical operations of 80 bed inpatient psychiatric hospital and Partial Hospitalization program ensuring patients receive safe, high-quality medical care

- Hire, coach and mentor physicians, engage physicians around quality assurance, utilization review and process improvement.

- Collaborate with CEO on strategic decisions and service line development to ensure quality management and promote optimum patient experience

MAY 2019 – PRESENT

CEO/OWNER, HOLISTIC MENTAL HEALTH, LLC • STUART, FL

- Primary provider in part time private practice specializing in treatment of mood disorders, peripartum disorders, cognitive disorders, and substance use disorders in adults and adolescents

SEPTEMBER 2018 – FEBRUARY 2019

ACTING MEDICAL DIRECTOR, TRIDENT HEALTH/ HCA · CHARLESTON, SC

- Directed 17-bed and 9-bed inpatient psychiatric units, a Partial Hospitalization Program, and busy Consultation service at Trident Health
- Lead role in Physician recruitment, quality improvement, instituting evidence based practices/reducing variation, improved patient satisfaction scores, decreased readmission rates, improve behavioral health patient flow through hospital system consisting of main emergency room and multiple freestanding emergency rooms.
- Active role in establishing community relationships/partnerships to improve access and quality of mental health services in the area

JULY 2014 – SEPTEMBER 2018

PSYCHIATRIC HOSPITALIST, TRIDENT HEALTH/ HCA · CHARLESTON, SC

- Participated in creation of new psychiatric inpatient program- LowCountry Transitions Trident- a 17 bed adult inpatient unit
- Developed physician coverage, improved morning staffing process, developed clinical protocols/procedures, and created inpatient psychiatric roles in a new program
- Improved overall supervision and staffing of psychiatric patients throughout the hospital by improving processes between ER Physicians, Crisis Intervention Team and Psychiatric MDs, which contributed to improved quality of care and decrease in ER boarding times of psychiatric patients
- Provided clinical supervision to behavioral health counselors as well as Nurse Practitioner

OCTOBER 2015 – FEBRUARY 2019

CEO/OWNER, ANISHA GULATI MD, LLC · CHARLESTON, SC

- Primary provider in private practice specializing in treatment of psychotic disorders, mood disorders, peripartum disorders, cognitive disorders, and substance use disorders in adults and adolescents

AUGUST 2016 – APRIL 2018

PSYCHIATRIST/FOUNDING BEHAVIORAL HEALTH MEDICAL DIRECTOR,

FETTER HEALTHCARE NETWORK · CHARLESTON, SC

- Worked alongside CMO Dr. Jenkins to develop behavioral health service line in an Integrated Care Model
- Helped assemble team and supervised 2 therapists, 1 psychologist, and 1 psychiatrist
- Developed behavioral health templates for new EHR
- Developed telepsychiatry services to provide services to satellite clinics in Fetter Healthcare Network

AUGUST 2005 – JUNE 2006

RESEARCH TECHNICIAN, THE SCRIPPS RESEARCH INSTITUTE · JUPITER, FL

- Genomics researcher focused on identifying genes involved in depression as well as genes involved in antidepressant response in order to identify new antidepressant drug targets

EDUCATION

JANUARY 2020- JUNE 2023

EXECUTIVE MBA HEALTHCARE LEADERSHIP AND MANAGEMENT, UNIVERSITY OF TEXAS, DALLAS

JULY 2010- JUNE 2014

PSYCHIATRIC RESIDENCY, UNIVERSITY OF NORTH CAROLINA HOSPITALS, CHAPEL HILL

JULY 2006- JUNE 2010

DOCTOR OF MEDICINE (M.D.), UNIVERSITY OF SOUTH ALABAMA

JUNE 2004- JULY 2005

MASTERS OF SCIENCE BIOMEDICAL SCIENCES, BOSTON UNIVERSITY SCHOOL OF MEDICINE

JUNE 2000- MAY 2004

BACHELORS DEGREE, PSYCHOLOGY, UNIVERSITY OF FLORIDA, GAINESVILLE
MINOR IN BUSINESS ADMINISTRATION

LICENSURE/CERTIFICATIONS

- Unrestricted Medical License- FL, NY, TN, TX
- Board Certified in General Psychiatry
- Institute for Healthcare improvement certification in Quality and Safety
- Suboxone prescribing waiver (DEA-X)
- Good Clinical Practice certification
- Fellowship in Reproductive Integrative Psychiatry

HONORS/AWARDS

Charleston Choice Best Psychiatrist Winner

▣ Masters Thesis Honors Distinction, Boston University

▣ Recipient, Bright Futures Academic Scholarship (funded 100% of undergraduate tuition)

VOLUNTEER WORK

- ✓ Tricity Family Ministries – Volunteer Psychiatrist
- ✓ Homestart Womens Homeless Shelter- Volunteer Psychiatrist, Chapel Hill, NC
- ✓ Community House Shelter- Volunteer Psychiatrist to residents of homeless shelter
- ✓ Housing for New Hope – provided psychiatric care to unsheltered

ADDITIONAL TRAINING

- ✓ UNC HOMELESS S.U.P.P.O.R.T. PROGRAM (Services For Unsheltered Persons and Psychiatric Outreach training)- helped found program which provided psychiatric care to street homeless in Chapel Hill Area in effort to treat hard to reach populations as well as ER super- utilizers
- 📄 Alcohol and Substance abuse treatment program (ASAP), Chapel Hill, trained in Medication- Assisted Substance treatment
- 📄 XDS ACTT (Cross Disabilities Assertive Community Treatment Team)- Orange County, NC- Worked as Psychiatrist on ACT team providing person- centered and flexible treatment for team of 100 patients with goal of assisting people with multiple disabilities to live in the community of their choice, achieve personal responsibility, and gain an enhanced quality of life
- ✓ Perinatal Psychiatry Inpatient Unit- UNC Hospitals- Received extensive training in perinatal psychiatry in first inpatient unit of its kind as well as provided psychiatric consults to Ob/Gyn Departments

PUBLICATIONS

- ✓ Miller BH, Schultz LE, **Gulati A**, Pletcher MT. Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety. PLoS One, 2010.
- ✓ Miller BH, Schultz LE, **Gulati A**, et al. Haplotype-based genetic analysis of behavioral despair in inbred mouse strains. BMC Biology, 2009.
- ✓ Schneyer AL, Sidis Y, **Gulati A** et al. Differential Antagonism of Activin, Myostatin, and GDF 11 by Wild Type and mutant Follistatin. Endocrinology 2008.
- ✓ Miller BH, Schultz LE, **Gulati A**, et al. Genetic Regulation of Behavioral and Neuronal Responses to Fluoxetine. Neuropsychopharmacology 2008.
- ✓ Fleisch S, **Gulati A**, Watson A. A UNC Homeless Support Program: Developing a Street Outreach Community Rotation for Psychiatry Residents. International Street Medicine Symposium. October 2013. Boston Oral/Poster Presentation
- ✓ Miller, B.H., **Gulati A**, and Pletcher, M.T. Strain-dependent behavioral and neuronal responses to fluoxetine. Neuroscience. Abstr., 2006
- ✓ Schneyer, A, Sidis, Y., Keutmann, H., **Gulati, A**, Sun, J., and Krasney, P. Follistatin Binding To Activin And Myostatin Involves Partially Distinct Contact Regions: Implications For Development Of Ligand-Specific Antagonists. The Endocrine Society's 89th Annual Meeting, Oral/Poster presentation, 2006
- ✓ Thesis: **Gulati, A**. Identification of Follistatin Mutations that Differentially Bind and Inhibit TGF- β Family Members Myostatin and Activin A (Funded by Pfizer, Inc.) Department of Reproductive Endocrinology, Harvard Medical School, 2005-2008. Thesis *Research Summary: My investigations identified molecules that can inhibit myostatin, a negative regulator of muscle growth, thereby increasing muscle mass, and therefore quality of health, in patients with disease related cachexia (ex. Cancer, AIDS patients) without the side effects resulting from concurrent inhibition of related proteins.*

✓ **Gulati, A.** Contributing author: How to build a meaningful mom tribe. Lowcountry Parent magazine. July 2018

CLINICAL RESEARCH EXPERIENCE

- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
- Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Study Drug / Study Drug for the Treatment of Negative Symptoms of Schizophrenia
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Study Drug in Obese Adult Patients with Schizophrenia Taking Antipsychotic Medications
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
- A Phase 3, 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of 2 Fixed Doses of Study Drug in the Treatment of Subjects with Agitation Associated with Dementia of Alzheimer's type
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)
- A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Study Drug for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in patients with traumatic brain injury (TBI)
- An Open-label Study of study drug in Adults with Major Depressive Disorder A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study to Investigate the Efficacy, Safety and Tolerability of Study Drug Adjunct to an Antidepressant in Participants with Treatment Resistant Depression
- The Efficacy, Safety and, Tolerability of Study Drug in Participants with Treatment Resistant Depression: A Long-Term Follow-Up Study, With Open-Label Treatment of Non-Responders and Those Who Experience a Depressive Release
- A Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of Study Drug in Adults with Schizophrenia
- A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Study Drug as Adjunctive Therapy to

Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy